Quality Assurance in Compounding, Explained

The standards that frame the work

The United States Pharmacopeia publishes the compounding standards most U.S. pharmacies work within. They are referenced by many state boards and form the backbone of a quality program. ¹ Three chapters do most of the heavy lifting.

• USP <795> sets standards for nonsterile compounding, including ingredients, procedures, and beyond-use dating. ¹
• USP <797> sets standards for sterile compounding, including environmental controls, personnel practices, and stricter beyond-use limits. ¹
• USP <800> addresses safe handling of hazardous drugs to protect personnel, patients, and the environment. ¹

Quality assurance (in compounding)

The system of procedures, documentation, environmental controls, training, and checks a pharmacy uses to make preparations consistently and safely against recognized standards. ¹

Beyond-use dating

Beyond-use date (BUD)

The date or time after which a compounded preparation should not be used, assigned based on factors set out in USP chapters such as the type of preparation and storage conditions. It is distinct from a manufacturer's expiration date. ¹

Beyond-use dating is a good example of process discipline. Rather than guessing how long a preparation is good for, the standards define how to assign a BUD, which is part of why documentation and controls matter. ¹ It is a quality practice, not a marketing claim, and that distinction is the theme of this whole article.

Testing and verification

Depending on the preparation and setting, quality programs may include things like environmental monitoring, end-product or third-party testing, and ingredient verification. ¹ Outsourcing facilities operating under section 503B of federal law are also held to Current Good Manufacturing Practice requirements overseen by the FDA, a higher bar than traditional patient-specific compounding. ² The right level of testing depends on the pharmacy's category and what it makes.

How to reference quality honestly in marketing

There is a real, defensible story in a strong quality program, and you can tell it without overclaiming. The trick is to describe process and adherence in factual terms and to avoid implying clinical results or regulatory status the process does not confer. ³

• Reasonable: "We compound in line with applicable USP standards" if that is accurate. ¹
• Reasonable: describing your environmental controls, training, and documentation factually. ¹
• Not reasonable: implying compounded preparations are approved by the FDA or "the same as" a brand drug. ³
• Not reasonable: turning a quality control into a clinical or efficacy claim about a product. ³
• Not reasonable: vague superlatives ("safest", "highest quality") you cannot substantiate. ³

A clean way to think about it: quality assurance is about how carefully you make things, verified against published standards. That is a legitimate and persuasive thing to communicate. It is not a license to make promises about how a preparation will perform for a patient, which remains a prescriber-and-patient matter.

This is an educational overview, not legal advice. USP chapters are revised over time and state adoption varies, so confirm the current versions and how they apply to you with USP and your state board of pharmacy, and run any marketing claims past qualified counsel. ¹²³